Experimental CAR-T therapy targets tough blood cancers
NCT ID NCT06208735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment called CLIC-2201 for people with B-cell cancers (like certain leukemias and lymphomas) that have come back or not responded to standard care. The treatment involves collecting a patient's own immune cells, modifying them to target a protein called CD22 on cancer cells, and infusing them back. The main goal is to find a safe dose and monitor side effects, with a secondary look at whether the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CLIC-2201 (a type of CAR-T cell therapy that targets CD22 on cancer cells)
- What this could lead to
- If this works, it could offer a new treatment option for people with B-cell cancers that have not responded to other therapies.
- What could go wrong
- This is a very early (Phase 1) trial with only 24 participants, so it is primarily checking safety. The therapy may not work or could cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alberta Children's Hospital
RECRUITINGCalgary, Alberta, T3B 6A8, Canada
-
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITINGCalgary, Alberta, T2N 5G2, Canada
-
BC Children's Hospital
RECRUITINGVancouver, British Columbia, Canada
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, Canada
-
The Hospital for Sick Children
RECRUITINGToronto, Ontario, Canada
-
The Ottawa Hospital - General Campus
RECRUITINGOttawa, Ontario, K1H 8L6, Canada
-
Vancouver General Hospital
RECRUITINGVancouver, British Columbia, V5Z 1M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?